Genetics of Gallstone Disease

Advances in Clinical Chemistry

Volumn 60, Issue , 2013, Pages 143-185

  Chuang, Shih Chang ^a,b   Hsi, Edward ^a,c   Lee, King Teh ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b Division of Hepatobiliary Pancreatic Surgery   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Bile; Gallstone; Genes; Mucin; Single nucleotide polymorphism

Indexed keywords

EID: 84875087122     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-407681-5.00005-2     Document Type: Chapter

References (190)

1. Everhart J.E., Yeh F., Lee E.T., et al. Prevalence of gallbladder disease in American Indian populations: findings from the Strong Heart Study. Hepatology 2002, 35:1507-1512.
2. Weiss K.M., Ferrell R.E., Hanis C.L., Styne P.N. Genetics and epidemiology of gallbladder disease in New World native peoples. Am. J. Hum. Genet. 1984, 36:1259-1278.
3. Sampliner R.E., Bennett P.H., Comess L.J., Rose F.A., Burch T.A. Gallbladder disease in pima Indians. Demonstration of high prevalence and early onset by cholecystography. N. Engl. J. Med. 1970, 283:1358-1364.
4. Lammert F., Sauerbruch T. Mechanisms of disease: the genetic epidemiology of gallbladder stones. Nat. Clin. Pract. Gastroenterol. Hepatol. 2005, 2:423-433.
5. Everhart J.E., Khare M., Hill M., Maurer K.R. Prevalence and ethnic differences in gallbladder disease in the United States. Gastroenterology 1999, 117:632-639.
6. Kratzer W., Mason R.A., Kachele V. Prevalence of gallstones in sonographic surveys worldwide. J. Clin. Ultrasound 1999, 27:1-7.
7. Wang D.Q.H., Afdhal N.H. Genetic analysis of cholesterol gallstone formation: searching for Lith (gallstone) genes. Curr. Gastroenterol. Rep. 2004, 6:140-150.
8. Vanderlinden W., Lindeloef G. The familial occurrence of gallstone disease. Acta Genet. Stat. Med. 1965, 15:159-164.
9. van der Linden W., Simonson N. Familial occurrence of gallstone disease. Incidence in parents of young patients. Hum. Hered. 1973, 23:123-127.
10. Sarin S.K., Negi V.S., Dewan R., Sasan S., Saraya A. High familial prevalence of gallstones in the first-degree relatives of gallstone patients. Hepatology 1995, 22:138-141.
11. Attili A.F., De Santis A., Attili F., Roda E., Festi D., Carulli N. Prevalence of gallstone disease in first-degree relatives of patients with cholelithiasis. World J. Gastroenterol. 2005, 11:6508-6511.
12. Antero Kesaniemi Y., Koskenvuo M., Vuoristo M., Miettinen T.A. Biliary lipid composition in monozygotic and dizygotic pairs of twins. Gut 1989, 30:1750-1756.
13. Duggirala R., Mitchell B.D., Blangero J., Stern M.P. Genetic determinants of variation in gallbladder disease in the Mexican-American population. Genet. Epidemiol. 1999, 16:191-204.
14. Katsika D., Grjibovski A., Einarsson C., Lammert F., Lichtenstein P., Marschall H.-U. Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43,141 twin pairs. Hepatology (Baltimore, MD) 2005, 41:1138-1143.
15. Pullinger C.R., Eng C., Salen G., et al. Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J. Clin. Invest. 2002, 110:109-117.
16. Marcil M., Brooks-Wilson A., Clee S.M., et al. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet 1999, 354:1341-1346.
17. Rosmorduc O., Hermelin B., Boelle P.Y., Parc R., Taboury J., Poupon R. ABCB4 gene mutation-associated cholelithiasis in adults. Gastroenterology 2003, 125:452-459.
18. Shoda J., Oda K., Suzuki H., et al. Etiologic significance of defects in cholesterol, phospholipid, and bile acid metabolism in the liver of patients with intrahepatic calculi. Hepatology 2001, 33:1194-1205.
19. King R.A., Rotter J.I., Motulsky A.G. The Genetic Basis of Common Diseases 2002, Oxford University Press, Oxford, NY. second ed.
20. Wang D.Q., Schmitz F., Kopin A.S., Carey M.C. Targeted disruption of the murine cholecystokinin-1 receptor promotes intestinal cholesterol absorption and susceptibility to cholesterol cholelithiasis. J. Clin. Invest. 2004, 114:521-528.
21. Pena-Quintana L., Garcia-Luzardo M.R., Garcia-Villarreal L., et al. Manifestations and evolution of Wilson disease in pediatric patients carrying ATP7B mutation L708P. J. Pediatr. Gastroenterol. Nutr. 2012, 54:48-54.
22. van der Woerd W.L., van Mil S.W., Stapelbroek J.M., Klomp L.W., van de Graaf S.F., Houwen R.H. Familial cholestasis: progressive familial intrahepatic cholestasis, benign recurrent intrahepatic cholestasis and intrahepatic cholestasis of pregnancy. Best Pract. Res. Clin. Gastroenterol. 2010, 24:541-553.
23. Wang D.Q., Paigen B., Carey M.C. Phenotypic characterization of Lith genes that determine susceptibility to cholesterol cholelithiasis in inbred mice: physical-chemistry of gallbladder bile. J. Lipid Res. 1997, 38:1395-1411.
24. Buch S., Schafmayer C., Volzke H., et al. A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat. Genet. 2007, 39:995-999.
25. Grunhage F., Acalovschi M., Tirziu S., et al. Increased gallstone risk in humans conferred by common variant of hepatic ATP-binding cassette transporter for cholesterol. Hepatology 2007, 46:793-801.
26. Lohse P., Brewer H.B., Meng M.S., Skarlatos S.I., LaRosa J.C., Brewer H.B. Familial apolipoprotein E deficiency and type III hyperlipoproteinemia due to a premature stop codon in the apolipoprotein E gene. J. Lipid Res. 1992, 33:1583-1590.
27. Niemi M., Kervinen K., Rantala A., et al. The role of apolipoprotein E and glucose intolerance in gallstone disease in middle aged subjects. Gut 1999, 44:557-562.
28. Bertomeu A., Ros E., Zambon D., et al. Apolipoprotein E polymorphism and gallstones. Gastroenterology 1996, 111:1603-1610.
29. Mella J.G., Schirin-Sokhan R., Rigotti A., et al. Genetic evidence that apolipoprotein E4 is not a relevant susceptibility factor for cholelithiasis in two high-risk populations. J. Lipid Res. 2007, 48:1378-1385.
30. Miettinen T.A., Gylling H., Vanhanen H., Ollus A. Cholesterol absorption, elimination, and synthesis related to LDL kinetics during varying fat intake in men with different apoprotein E phenotypes. Arterioscler. Thromb. 1992, 12:1044-1052.
31. Srivastava A., Srivastava K., Choudhuri G., Mittal B. Role of ABCG8 D19H (rs11887534) variant in gallstone susceptibility in northern India. J. Gastroenterol. Hepatol. 2010, 25:1758-1762.
32. Siddapuram S.P., Mahurkar S., Duvvuru N.R., et al. Hepatic cholesterol transporter ABCG8 polymorphisms in gallstone disease in an Indian population. J. Gastroenterol. Hepatol. 2010, 25:1093-1098.
33. Kuo K.K., Shin S.J., Chen Z.C., Yang Y.H.C., Yang J.F., Hsiao P.J. Significant association of ABCG5 604Q and ABCG8 D19H polymorphisms with gallstone disease. Br. J. Surg. 2008, 95:1005-1011.
34. Wang H.H., Patel S.B., Carey M.C., Wang D.Q. Quantifying anomalous intestinal sterol uptake, lymphatic transport, and biliary secretion in Abcg8(-/-) mice. Hepatology 2007, 45:998-1006.
35. Kurzawski M., Juzyszyn Z., Modrzejewski A., et al. Apolipoprotein B (APOB) gene polymorphism in patients with gallbladder disease. Arch. Med. Res. 2007, 38:360-363.
36. Dixit M., Choudhuri G., Saxena R., Mittal B. Association of apolipoprotein A1-C3 gene cluster polymorphisms with gallstone disease. Can. J. Gastroenterol 2007, 21:569-575.
37. Dixit M., Choudhuri G., Mittal B. Association of APOE-C1 gene cluster polymorphisms with gallstone disease. Dig. Liver Dis. 2006, 38:397-403.
38. Jiang Z.Y., Han T.Q., Suo G.J., et al. Polymorphisms at cholesterol 7alpha-hydroxylase, apolipoproteins B and E and low density lipoprotein receptor genes in patients with gallbladder stone disease. World J. Gastroenterol. 2004, 10:1508-1512.
39. Han T., Jiang Z., Suo G., Zhang S. Apolipoprotein B-100 gene Xba I polymorphism and cholesterol gallstone disease. Clin. Genet. 2000, 57:304-308.
40. Baez S., Tsuchiya Y., Calvo A., et al. Genetic variants involved in gallstone formation and capsaicin metabolism, and the risk of gallbladder cancer in Chilean women. World J. Gastroenterol. 2010, 16:372-378.
41. Pandey S.N., Dixit M., Choudhuri G., Mittal B. Lipoprotein receptor associated protein (LRPAP1) insertion/deletion polymorphism: association with gallbladder cancer susceptibility. Int. J. Gastrointest. Cancer 2006, 37:124-128.
42. Dixit M., Choudhuri G., Keshri L.J., Mittal B. Association of low density lipoprotein receptor related protein-associated protein (LRPAP1) gene insertion/deletion polymorphism with gallstone disease. J. Gastroenterol. Hepatol. 2006, 21:847-849.
43. Chen Q., Li W.J., Wan Y.Y., Yu C.D., Li W.G. Fibroblast growth factor receptor 4 Gly388Arg polymorphism associated with severity of gallstone disease in a Chinese population. Genet. Mol. Res. 2012, 11:548-555.
44. Nakamoto K., Wang S., Jenison R.D., et al. Linkage disequilibrium blocks, haplotype structure, and htSNPs of human CYP7A1 gene. BMC Genet. 2006, 7:29.
45. Srivastava A., Srivastava N., Choudhuri G., Mittal B. Organic anion transporter 1B1 (SLCO1B1) polymorphism and gallstone formation: high incidence of Exon4 CA genotype in female patients in North India. Hepatol. Res. 2011, 41:71-78.
46. Renner O., Harsch S., Schaeffeler E., et al. A variant of the SLC10A2 gene encoding the apical sodium-dependent bile acid transporter is a risk factor for gallstone disease. PLoS One 2009, 4:e7321.
47. Kovacs P., Kress R., Rocha J., et al. Variation of the gene encoding the nuclear bile salt receptor FXR and gallstone susceptibility in mice and humans. J. Hepatol. 2008, 48:116-124.
48. Heeney M.M., Howard T.A., Zimmerman S.A., Ware R.E. UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia. J. Lab. Clin. Med. 2003, 141:279-282.
49. Passon R.G., Howard T.A., Zimmerman S.A., Schultz W.H., Ware R.E. Influence of bilirubin uridine diphosphate-glucuronosyltransferase 1A promoter polymorphisms on serum bilirubin levels and cholelithiasis in children with sickle cell anemia. J. Pediatr. Hematol. Oncol. 2001, 23:448-451.
50. Chuang S.C., Juo S.H., Hsi E., et al. Multiple mucin genes polymorphisms are associated with gallstone disease in Chinese men. Clin. Chim. Acta 2011, 412:599-603.
51. Chuang S.C., Hsi E., Wang S.N., Yu M.L., Lee K.T., Juo S.H. Polymorphism at the mucin-like protocadherin gene influences susceptibility to gallstone disease. Clin. Chim. Acta 2011, 412:2089-2093.
52. Srivastava A., Pandey S.N., Dixit M., Choudhuri G., Mittal B. Cholecystokinin receptor A gene polymorphism in gallstone disease and gallbladder cancer. J. Gastroenterol. Hepatol. 2008, 23:970-975.
53. Klass D.M., Lauer N., Hay B., Kratzer W., Fuchs M. Arg64 variant of the beta3-adrenergic receptor is associated with gallstone formation. Am. J. Gastroenterol. 2007, 102:2482-2487.
54. Kitsiou-Tzeli S., Giannatou E., Spanos I., et al. Steroid hormones polymorphisms and cholelithiasis in Greek population. Liver Int. 2007, 27:61-68.
55. Wang Y., Jiang Z.Y., Fei J., et al. ATP binding cassette G8 T400K polymorphism may affect the risk of gallstone disease among Chinese males. Clin. Chim. Acta 2007, 384:80-85.
56. Wang H.H., Portincasa P., Afdhal N.H., Wang D.Q.H. Lith genes and genetic analysis of cholesterol gallstone formation. Gastroenterol. Clin. North Am. 2010, 39:185-207.
57. Khanuja B., Cheah Y.C., Hunt M., et al. Lith1, a major gene affecting cholesterol gallstone formation among inbred strains of mice. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:7729-7733.
58. Aldinger K.A., Sokoloff G., Rosenberg D.M., Palmer A.A., Millen K.J. Genetic variation and population substructure in outbred CD-1 mice: implications for genome-wide association studies. PLoS One 2009, 4:e4729.
59. Yalcin B., Nicod J., Bhomra A., et al. Commercially available outbred mice for genome-wide association studies. PLoS Genet. 2010, 6(9):e1001085.
60. Zhang W., Korstanje R., Thaisz J., et al. Genomewide association mapping of quantitative traits in outbred mice. G3 (Bethesda) 2012, 2:167-174.
61. Small D.M. Cholesterol nucleation and growth in gallstone formation. N. Engl. J. Med. 1980, 302:1305-1307.
62. Fujihira E., Kaneta S., Ohshima T. Strain difference in mouse cholelithiasis and the effect of taurine on the gallstone formation in C57BL/C mice. Biochem. Med. 1978, 19:211-217.
63. Tepperman J., Caldwell F.T., Tepperman H.M. Induction of gallstones in mice by feeding a cholesterol-cholic acid containing diet. Am. J. Physiol. 1964, 206:628-634.
64. Wang H.H., Portincasa P., Mendez-Sanchez N., Uribe M., Wang D.Q. Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones. Gastroenterology 2008, 134:2101-2110.
65. Buhman K.K., Accad M., Novak S., et al. Resistance to diet-induced hypercholesterolemia and gallstone formation in ACAT2-deficient mice. Nat. Med. 2000, 6:1341-1347.
66. Lyons M.A., Wittenburg H. Cholesterol gallstone susceptibility loci: a mouse map, candidate gene evaluation, and guide to human LITH genes. Gastroenterology 2006, 131:1943-1970.
67. Lammert F., Carey M.C., Paigen B. Chromosomal organization of candidate genes involved in cholesterol gallstone formation: a murine gallstone map. Gastroenterology 2001, 120:221-238.
68. Holan K.R., Holzbach R.T., Hermann R.E., Cooperman A.M., Claffey W.J. Nucleation time: a key factor in the pathogenesis of cholesterol gallstone disease. Gastroenterology 1979, 77:611-617.
69. Levy P.F., Smith B.F., LaMont J.T. Human gallbladder mucin accelerates nucleation of cholesterol in artificial bile. Gastroenterology 1984, 87:270-275.
70. Wittenburg H. Hereditary liver disease: gallstones. Best Pract. Res. Clin. Gastroenterol. 2010, 24:747-756.
71. Portincasa P., Moschetta A., Palasciano G. Cholesterol gallstone disease. Lancet 2006, 368:230-239.
72. Van Erpecum K.J., Van Berge-Henegouwen G.P. Gallstones: an intestinal disease?. Gut 1999, 44:435-438.
73. Portincasa P., van Erpecum K.J., Vanberge-Henegouwen G.P. Cholesterol crystallisation in bile. Gut 1997, 41:138-141.
74. Robins S.J., Fasulo J.M. High density lipoproteins, but not other lipoproteins, provide a vehicle for sterol transport to bile. J. Clin. Invest. 1997, 99:380-384.
75. Cooper A.D. Hepatic uptake of chylomicron remnants. J. Lipid Res. 1997, 38:2173-2192.
76. Hillebrant C.G., Nyberg B., Einarsson K., Eriksson M. The effect of plasma low density lipoprotein apheresis on the hepatic secretion of biliary lipids in humans. Gut 1997, 41:700-704.
77. Davis H.R., Zhu L.J., Hoos L.M., et al. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J. Biol. Chem. 2004, 279:33586-33592.
78. Altmann S.W., Davis H.R., Zhu L.J., et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004, 303:1201-1204.
79. Berge K.E., Tian H., Graf G.A., et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000, 290:1771-1775.
80. Horton J.D., Shah N.A., Warrington J.A., et al. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:12027-12032.
81. Schmitz G., Langmann T. Structure, function and regulation of the ABC1 gene product. Curr. Opin. Lipidol. 2001, 12:129-140.
82. Repa J.J., Turley S.D., Lobaccaro J.A., et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000, 289:1524-1529.
83. Tessner T.G., Stenson W.F. Overexpression of MDR1 in an intestinal cell line results in increased cholesterol uptake from micelles. Biochem. Biophys. Res. Commun. 2000, 267:565-571.
84. Jolley C.D., Dietschy J.M., Turley S.D. Induction of bile acid synthesis by cholesterol and cholestyramine feeding is unimpaired in mice deficient in apolipoprotein AI. Hepatology 2000, 32:1309-1316.
85. Mittal B., Mittal R.D. Genetics of gallstone disease. J. Postgrad. Med. 2002, 48:149-152.
86. Gautier T., Masson D., de Barros J.P., et al. Human apolipoprotein C-I accounts for the ability of plasma high density lipoproteins to inhibit the cholesteryl ester transfer protein activity. J. Biol. Chem. 2000, 275:37504-37509.
87. Amigo L., Quinones V., Mardones P., et al. Impaired biliary cholesterol secretion and decreased gallstone formation in apolipoprotein E-deficient mice fed a high-cholesterol diet. Gastroenterology 2000, 118:772-779.
88. Juvonen T., Savolainen M.J., Kairaluoma M.I., Lajunen L.H., Humphries S.E., Kesaniemi Y.A. Polymorphisms at the apoB, apoA-I, and cholesteryl ester transfer protein gene loci in patients with gallbladder disease. J. Lipid Res. 1995, 36:804-812.
89. Acton S., Rigotti A., Landschulz K.T., Xu S., Hobbs H.H., Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996, 271:518-520.
90. Fuchs M., Ivandic B., Muller O., et al. Biliary cholesterol hypersecretion in gallstone-susceptible mice is associated with hepatic up-regulation of the high-density lipoprotein receptor SRBI. Hepatology 2001, 33:1451-1459.
91. Chang C.C., Sakashita N., Ornvold K., et al. Immunological quantitation and localization of ACAT-1 and ACAT-2 in human liver and small intestine. J. Biol. Chem. 2000, 275:28083-28092.
92. Kullak-Ublick G.A., Stieger B., Meier P.J. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 2004, 126:322-342.
93. Kalaany N.Y., Mangelsdorf D.J. LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu. Rev. Physiol. 2006, 68:159-191.
94. Li T., Chiang J.Y. Regulation of bile acid and cholesterol metabolism by PPARs. PPAR Res. 2009, 2009:501739.
95. Quinn C.M., Jessup W., Wong J., Kritharides L., Brown A.J. Expression and regulation of sterol 27-hydroxylase (CYP27A1) in human macrophages: a role for RXR and PPARgamma ligands. Biochem. J. 2005, 385:823-830.
96. Stedman C., Liddle C., Coulter S., et al. Benefit of farnesoid X receptor inhibition in obstructive cholestasis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:11323-11328.
97. Wang R., Salem M., Yousef I.M., et al. Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in nonprogressive but persistent intrahepatic cholestasis. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:2011-2016.
98. Smit J.J., Schinkel A.H. Oude Elferink RP, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993, 75:451-462.
99. Yu P., Chen Q., Xiao Z., Harnett K., Biancani P., Behar J. Signal transduction pathways mediating CCK-induced gallbladder muscle contraction. Am. J. Physiol. 1998, 275:G203-G211.
100. Wang D.Q., Zhang L., Wang H.H. High cholesterol absorption efficiency and rapid biliary secretion of chylomicron remnant cholesterol enhance cholelithogenesis in gallstone-susceptible mice. Biochim. Biophys. Acta 2005, 1733:90-99.
101. Lammert F., Wang D.Q. New insights into the genetic regulation of intestinal cholesterol absorption. Gastroenterology 2005, 129:718-734.
102. Lawn R.M., Wade D.P., Couse T.L., Wilcox J.N. Localization of human ATP-binding cassette transporter 1 (ABC1) in normal and atherosclerotic tissues. Arterioscler. Thromb. Vasc. Biol. 2001, 21:378-385.
103. Barter P.J., Brewer H.B., Chapman M.J., Hennekens C.H., Rader D.J., Tall A.R. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2003, 23:160-167.
104. Ji Y., Wang N., Ramakrishnan R., et al. Hepatic scavenger receptor BI promotes rapid clearance of high density lipoprotein free cholesterol and its transport into bile. J. Biol. Chem. 1999, 274:33398-33402.
105. Kozarsky K.F., Donahee M.H., Rigotti A., Iqbal S.N., Edelman E.R., Krieger M. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature 1997, 387:414-417.
106. Nielsen P.R., Ellgaard L., Etzerodt M., Thogersen H.C., Poulsen F.M. The solution structure of the N-terminal domain of alpha2-macroglobulin receptor-associated protein. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:7521-7525.
107. Robins S.J., Fasulo J.M., Lessard P.D., Patton G.M. Hepatic cholesterol synthesis and the secretion of newly synthesized cholesterol in bile. Biochem. J. 1993, 289(Pt. 1):41-44.
108. Empen K., Lange K., Stange E.F., Scheibner J. Newly synthesized cholesterol in human bile and plasma: quantitation by mass isotopomer distribution analysis. Am. J. Physiol. 1997, 272:G367-G373.
109. Smit J.W., VanErpecum K.J., VanBerge-Henegouwen G.P. Cholesterol synthesis inhibitors in cholesterol gallstone disease. Scand. J. Gastroenterol. Suppl. 1996, 218:56-60.
110. Chang T.Y., Chang C.C., Cheng D. Acyl-coenzyme A:cholesterol acyltransferase. Annu. Rev. Biochem. 1997, 66:613-638.
111. Meiner V., Tam C., Gunn M.D., et al. Tissue expression studies on the mouse acyl-CoA: cholesterol acyltransferase gene (Acact): findings supporting the existence of multiple cholesterol esterification enzymes in mice. J. Lipid Res. 1997, 38:1928-1933.
112. Anderson R.A., Joyce C., Davis M., et al. Identification of a form of acyl-CoA:cholesterol acyltransferase specific to liver and intestine in nonhuman primates. J. Biol. Chem. 1998, 273:26747-26754.
113. Yu L., Li-Hawkins J., Hammer R.E., et al. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J. Clin. Invest. 2002, 110:671-680.
114. Gerloff T., Stieger B., Hagenbuch B., et al. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J. Biol. Chem. 1998, 273:10046-10050.
115. Russell D.W., Setchell K.D. Bile acid biosynthesis. Biochemistry 1992, 31:4737-4749.
116. Bjorkhem I. Mechanism of degradation of the steroid side chain in the formation of bile acids. J. Lipid Res. 1992, 33:455-471.
117. Chiang J.Y. Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr. Rev. 2002, 23:443-463.
118. Admirand W.H., Small D.M. The physicochemical basis of cholesterol gallstone formation in man. J. Clin. Invest. 1968, 47:1043-1052.
119. Hofmann A.F. Biliary secretion and excretion in health and disease: current concepts. Ann. Hepatol. 2007, 6:15-27.
120. Hofmann A. Bile acid secretion, bile flow and biliary lipid secretion in humans. Hepatology (Baltimore, MD) 1990, 12:17S.
121. Frijters C.M., Ottenhoff R., van Wijland M.J., van Nieuwkerk C.M., Groen A.K., Oude Elferink R.P. Regulation of mdr2 P-glycoprotein expression by bile salts. Biochem. J. 1997, 321(Pt. 2):389-395.
122. Rosmorduc O., Hermelin B., Poupon R. MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology 2001, 120:1459-1467.
123. Lammert F., Wang D.Q., Hillebrandt S., et al. Spontaneous cholecysto- and hepatolithiasis in Mdr2-/- mice: a model for low phospholipid-associated cholelithiasis. Hepatology 2004, 39:117-128.
124. Allen A., Flemstrom G., Garner A., Kivilaakso E. Gastroduodenal mucosal protection. Physiol. Rev. 1993, 73:823-857.
125. Moniaux N., Escande F., Porchet N., Aubert J.P., Batra S.K. Structural organization and classification of the human mucin genes. Front. Biosci. 2001, 6:D1192-D1206.
126. Slomiany B.L., Zdebska E., Slomiany A. Structural characterization of neutral oligosaccharides of human H+Leb+ gastric mucin. J. Biol. Chem. 1984, 259:2863-2869.
127. Sasaki M., Ikeda H., Nakanuma Y. Expression profiles of MUC mucins and trefoil factor family (TFF) peptides in the intrahepatic biliary system: physiological distribution and pathological significance. Prog. Histochem. Cytochem. 2007, 42:61-110.
128. Keicho N., Hijikata M. Genetic predisposition to diffuse panbronchiolitis. Respirology 2011, 16:581-588.
129. Paris M.J., Williams B.R. Characterization of a 500-kb contig spanning the region between c-Ha-Ras and MUC2 on chromosome 11p15.5. Genomics 2000, 69:196-202.
130. Pigny P., Guyonnet-Duperat V., Hill A.S., et al. Human mucin genes assigned to 11p15.5: identification and organization of a cluster of genes. Genomics 1996, 38:340-352.
131. Sheen P.C., Lee K.T., Liu Y.E. Mucin content in gallbladders with brown pigment stones or combination stones with a brown periphery. Digestion 1998, 59:660-664.
132. Lee K.T., Liu T.S. Mucin gene expression in gallbladder epithelium with black pigment stone ascertained by in situ hybridization. Kaohsiung J. Med. Sci. 2001, 17:517-523.
133. Buisine M.P., Devisme L., Degand P., et al. Developmental mucin gene expression in the gastroduodenal tract and accessory digestive glands. II. Duodenum and liver, gallbladder, and pancreas. J. Histochem. Cytochem. 2000, 48:1667-1676.
134. Vilkin A., Nudelman I., Morgenstern S., et al. Gallbladder inflammation is associated with increase in mucin expression and pigmented stone formation. Dig. Dis. Sci. 2007, 52:1613-1620.
135. Afdhal N.H., Offner G.D., Murray F.E., Troxler R.F., Smith B.F. Isolation and characterization of peptides from the protein core of bovine gallbladder mucin. Gastroenterology 1990, 98:1633-1641.
136. Lee K.-T., Liu T.-S. Mucin gene expression in gallbladder epithelium. J. Formos. Med. Assoc. 2002, 101:762-768.
137. van Klinken B.J., Dekker J., van Gool S.A., van Marle J., Büller H.A., Einerhand A.W. MUC5B is the prominent mucin in human gallbladder and is also expressed in a subset of colonic goblet cells. Am. J. Physiol. 1998, 274:G871-G878.
138. Ho S.B., Shekels L.L., Toribara N.W., et al. Altered mucin core peptide expression in acute and chronic cholecystitis. Dig. Dis. Sci. 2000, 45:1061-1071.
139. Hulten O. Formation of gallstones. II. Acta Chir. Scand. 1968, 134:557-561.
140. Womack N.A., Zeppa R., Irvin G.L. The anatomy of gallstones. Ann. Surg. 1963, 157:670-686.
141. Womack N.A. The development of gallstones. Surg. Gynecol. Obstet. 1971, 133:937-945.
142. Englert E., Harman C.G., Freston J.W., Straight R.C., Wales E.E. Studies on the pathogenesis of diet-induced dog gallstones. Am. J. Dig. Dis. 1977, 22:305-314.
143. Freston J.W., Bouchier I.A., Newman J. Biliary mucous substances in dihydrocholesterol-induced cholelithiasis. Gastroenterology 1969, 57:670-678.
144. Lee S.P., LaMont J.T., Carey M.C. Role of gallbladder mucus hypersecretion in the evolution of cholesterol gallstones. J. Clin. Invest. 1981, 67:1712-1723.
145. Smith B.F., LaMont J.T. Identification of gallbladder mucin-bilirubin complex in human cholesterol gallstone matrix. Effects of reducing agents on in vitro dissolution of matrix and intact gallstones. J. Clin. Invest. 1985, 76:439-445.
146. Bar Dayan Y., Vilkin A., Niv Y. Gallbladder mucin plays a role in gallstone formation. Eur. J. Intern. Med. 2004, 15:411-414.
147. Maurer K.J., Carey M.C., Fox J.G. Roles of infection, inflammation, and the immune system in cholesterol gallstone formation. Gastroenterology 2009, 136:425-440.
148. Rege R.V., Prystowsky J.B. Inflammation and a thickened mucus layer in mice with cholesterol gallstones. J. Surg. Res. 1998, 74:81-85.
149. Thornton D.J., Sheehan J.K. From mucins to mucus: toward a more coherent understanding of this essential barrier. Proc. Am. Thorac. Soc. 2004, 1:54-61.
150. Jüngst C., Sreejayan N., Eder M.I., et al. Lipid peroxidation and mucin secretagogue activity in bile of gallstone patients. Eur. J. Clin. Invest. 2007, 37:731-736.
151. Finzi L., Barbu V., Burgel P.R., et al. MUC5AC, a gel-forming mucin accumulating in gallstone disease, is overproduced via an epidermal growth factor receptor pathway in the human gallbladder. Am. J. Pathol. 2006, 169:2031-2041.
152. Song K.S., Lee W.J., Chung K.C., et al. Interleukin-1 beta and tumor necrosis factor-alpha induce MUC5AC overexpression through a mechanism involving ERK/p38 mitogen-activated protein kinases-MSK1-CREB activation in human airway epithelial cells. J. Biol. Chem. 2003, 278:23243-23250.
153. Gray T., Nettesheim P., Loftin C., et al. Interleukin-1beta-induced mucin production in human airway epithelium is mediated by cyclooxygenase-2, prostaglandin E2 receptors, and cyclic AMP-protein kinase A signaling. Mol. Pharmacol. 2004, 66:337-346.
154. Maurer K.J., Rao V.P., Ge Z., et al. T-cell function is critical for murine cholesterol gallstone formation. Gastroenterology 2007, 133:1304-1315.
155. Levine S.J., Larivee P., Logun C., Angus C.W., Ognibene F.P., Shelhamer J.H. Tumor necrosis factor-alpha induces mucin hypersecretion and MUC-2 gene expression by human airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 1995, 12:196-204.
156. Zen Y., Harada K., Sasaki M., et al. Lipopolysaccharide induces overexpression of MUC2 and MUC5AC in cultured biliary epithelial cells: possible key phenomenon of hepatolithiasis. Am. J. Pathol. 2002, 161:1475-1484.
157. Kim Y.D., Jeon J.Y., Woo H.J., et al. Interleukin-1beta induces MUC2 gene expression and mucin secretion via activation of PKC-MEK/ERK, and PI3K in human airway epithelial cells. J. Korean Med. Sci. 2002, 17:765-771.
158. Bai C.H., Song S.Y., Kim Y.D. The inhibitory effect of the leukotriene receptor antagonist on leukotriene D4-induced MUC2/5AC gene expression and mucin secretion in human airway epithelial cells. Auris Nasus Larynx 2007, 34:203-206.
159. Afdhal N.H., Niu N., Nunes D.P., et al. Mucin-vesicle interactions in model bile: evidence for vesicle aggregation and fusion before cholesterol crystal formation. Hepatology 1995, 22:856-865.
160. LaMont J.T., Smith B.F., Moore J.R. Role of gallbladder mucin in pathophysiology of gallstones. Hepatology (Baltimore, MD) 1984, 4:51S-56S.
161. Sasaki M., Nakanuma Y., Kim Y.S. Expression of apomucins in the intrahepatic biliary tree in hepatolithiasis differs from that in normal liver and extrahepatic biliary obstruction. Hepatology 1998, 27:54-61.
162. Ganesh I.M., Subramani D., Halagowder D. Mucin glycoarray in gastric and gallbladder epithelia. J. Carcinog. 2007, 6:10.
163. Lee K.T., Liu T.S. Altered mucin gene expression in stone-containing intrahepatic bile ducts and cholangiocarcinomas. Dig. Dis. Sci. 2001, 46:2166-2172.
164. Lee S.P., Lim T.H., Scott A.J. Carbohydrate moieties of glycoproteins in human hepatic and gall-bladder bile, gall-bladder mucosa and gall stones. Clin. Sci. 1979, 56:533-538.
165. Bouchier I.A., Cooperband S.R. The characteristics of " white bile". Gastroenterology 1965, 49:354-359.
166. Lee T.J., Smith B.F. Bovine gallbladder mucin promotes cholesterol crystal nucleation from cholesterol-transporting vesicles in supersaturated model bile. J. Lipid Res. 1989, 30:491-498.
167. LaMont J.T., Ventola A.S., Trotman B.W., Soloway R.D. Mucin glycoprotein content of human pigment gallstones. Hepatology 1983, 3:377-382.
168. Kim H.J., Kim S.H., Chae G.B., Lee S.J., Kang C.D. Increased expression of mucin 5AC mRNA and decreased expression of epidermal growth-factor receptor mRNA in gallstone patients. Tohoku J. Exp. Med. 2008, 214:139-144.
169. Carlei F., Lygidakis N.J., Barsotti P., et al. Mucin-producing cells and endocrine cells of gallbladder epithelium in patients with uncomplicated cholelithiasis. Hepatogastroenterology 1991, 38:149-153.
170. Yamagiwa H., Tomiyama H. Intestinal metaplasia-dysplasia-carcinoma sequence of the gallbladder. Acta Pathol. Jpn. 1986, 36:989-997.
171. Albores-Saavedra J., Nadji M., Henson D.E., Ziegels-Weissman J., Mones J.M. Intestinal metaplasia of the gallbladder: a morphologic and immunocytochemical study. Hum. Pathol. 1986, 17:614-620.
172. Kim H.J., Kim J.S., Kim K.O., et al. Expression of MUC3, MUC5AC, MUC6 and epidermal growth factor receptor in gallbladder epithelium according to gallstone composition. Korean J. Gastroenterol. 2003, 42:330-336.
173. Vilkin A., Geller A., Levi Z., Niv Y. Mucin gene expression in bile of patients with and without gallstone disease, collected by endoscopic retrograde cholangiography. World J. Gastroenterol. 2009, 15:2367-2371.
174. LaMont J.T., Turner B.S., DiBenedetto D., Handin R., Schafer A.I. Arachidonic acid stimulates mucin secretion in prairie dog gallbladder. Am. J. Physiol. 1983, 245:G92-G98.
175. Lee S.P., Carey M.C., LaMont J.T. Aspirin prevention of cholesterol gallstone formation in prairie dogs. Science (New York, NY) 1981, 211:1429-1431.
176. Rhodes M., Allen A., Lennard T.W. Mucus glycoprotein biosynthesis in the human gall bladder: inhibition by aspirin. Gut 1992, 33:1109-1112.
177. Broomfield P.H., Chopra R., Sheinbaum R.C., et al. Effects of ursodeoxycholic acid and aspirin on the formation of lithogenic bile and gallstones during loss of weight. N. Engl. J. Med. 1988, 319:1567-1572.
178. Rhodes M., Allen A., Dowling R.H., Murphy G., Lennard T.W. Inhibition of human gall bladder mucus synthesis in patients undergoing cholecystectomy. Gut 1992, 33:1113-1117.
179. Jüngst C., Sreejayan N., Zündt B., et al. Ursodeoxycholic acid reduces lipid peroxidation and mucin secretagogue activity in gallbladder bile of patients with cholesterol gallstones. Eur. J. Clin. Invest. 2008, 38:634-639.
180. Gendler S.J., Spicer A.P., Gendler S.J., Spicer A.P. Epithelial mucin genes. Annu. Rev. Physiol. 1995, 57:607-634.
181. Verma M., Davidson E.A. Mucin genes: structure, expression and regulation. Glycoconj. J. 1994, 11:172-179.
182. Szoka P.R., Paigen K. Genetic regulation of mup production in recombinant inbred mice. Genetics 1979, 93:173-181.
183. Wang H.H., Afdhal N.H., Gendler S.J., Wang D.Q.H. Evidence that gallbladder epithelial mucin enhances cholesterol cholelithogenesis in MUC1 transgenic mice. Gastroenterology 2006, 131:210-222.
184. Yau W.M., Youther M.L. Modulation of gallbladder motility by intrinsic cholinergic neurons. Am. J. Physiol. 1984, 247:G662-G666.
185. Graewin S.J., Tran K.Q., Naggert J.K., et al. Diminished gallbladder motility in Rotund leptin-resistant obese mice. HPB (Oxford) 2005, 7:139-143.
186. Wang H.H., Afdhal N.H., Gendler S.J., Wang D.Q. Targeted disruption of the murine mucin gene 1 decreases susceptibility to cholesterol gallstone formation. J. Lipid Res. 2004, 45:438-447.
187. Hanyu N., Dodds W.J., Layman R.D., Hogan W.J., Chey W.Y., Takahashi I. Mechanism of cholecystokinin-induced contraction of the opossum gallbladder. Gastroenterology 1990, 98:1299-1306.
188. Miller L.J., Holicky E.L., Ulrich C.D., Wieben E.D. Abnormal processing of the human cholecystokinin receptor gene in association with gallstones and obesity. Gastroenterology 1995, 109:1375-1380.
189. Schneider H., Sanger P., Hanisch E. In vitro effects of cholecystokinin fragments on human gallbladders. Evidence for an altered CCK-receptor structure in a subgroup of patients with gallstones. J. Hepatol. 1997, 26:1063-1068.
190. Stengel P.W., Cohen M.L. Muscarinic receptor knockout mice: role of muscarinic acetylcholine receptors M(2), M(3), and M(4) in carbamylcholine-induced gallbladder contractility. J. Pharmacol. Exp. Ther. 2002, 301:643-650.